ES2560809T3 - Diagnóstico de lupus eritematoso sistémico - Google Patents
Diagnóstico de lupus eritematoso sistémico Download PDFInfo
- Publication number
- ES2560809T3 ES2560809T3 ES11711144.3T ES11711144T ES2560809T3 ES 2560809 T3 ES2560809 T3 ES 2560809T3 ES 11711144 T ES11711144 T ES 11711144T ES 2560809 T3 ES2560809 T3 ES 2560809T3
- Authority
- ES
- Spain
- Prior art keywords
- reactivity
- systemic lupus
- lupus erythematosus
- collagen
- antigens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000000596 systemic lupus erythematosus Diseases 0.000 title abstract description 8
- 238000003745 diagnosis Methods 0.000 title description 2
- 108020004414 DNA Proteins 0.000 abstract description 12
- 102000053602 DNA Human genes 0.000 abstract description 9
- 230000009257 reactivity Effects 0.000 abstract description 9
- 102000008186 Collagen Human genes 0.000 abstract description 8
- 108010035532 Collagen Proteins 0.000 abstract description 8
- 239000000427 antigen Substances 0.000 abstract description 8
- 229920001436 collagen Polymers 0.000 abstract description 8
- 102000036639 antigens Human genes 0.000 abstract description 7
- 108091007433 antigens Proteins 0.000 abstract description 7
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract description 4
- 102000007469 Actins Human genes 0.000 abstract description 4
- 108010085238 Actins Proteins 0.000 abstract description 4
- 102100037674 Bis(5'-adenosyl)-triphosphatase Human genes 0.000 abstract description 4
- 102000024905 CD99 Human genes 0.000 abstract description 4
- 108060001253 CD99 Proteins 0.000 abstract description 4
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 abstract description 4
- 108010005713 bis(5'-adenosyl)triphosphatase Proteins 0.000 abstract description 4
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 abstract description 4
- 229920002674 hyaluronan Polymers 0.000 abstract description 4
- 229960003160 hyaluronic acid Drugs 0.000 abstract description 4
- 101001081567 Homo sapiens Insulin-like growth factor-binding protein 1 Proteins 0.000 abstract description 3
- 102100027636 Insulin-like growth factor-binding protein 1 Human genes 0.000 abstract description 3
- 239000000523 sample Substances 0.000 abstract 3
- 102100039292 Cbp/p300-interacting transactivator 1 Human genes 0.000 abstract 2
- 101000888413 Homo sapiens Cbp/p300-interacting transactivator 1 Proteins 0.000 abstract 2
- 102000007460 S100 Calcium-Binding Protein A4 Human genes 0.000 abstract 2
- 108010085149 S100 Calcium-Binding Protein A4 Proteins 0.000 abstract 2
- 239000013068 control sample Substances 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 5
- 230000009266 disease activity Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 102000003896 Myeloperoxidases Human genes 0.000 description 3
- 108090000235 Myeloperoxidases Proteins 0.000 description 3
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000004375 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 2
- 108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 description 2
- 208000007117 Oral Ulcer Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000272522 Anas Species 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 101000933607 Homo sapiens Protein BTG3 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 206010058556 Serositis Diseases 0.000 description 1
- 230000003429 anti-cardiolipin effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 201000004997 drug-induced lupus erythematosus Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 102000028718 growth factor binding proteins Human genes 0.000 description 1
- 108091009353 growth factor binding proteins Proteins 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 108700039582 histidine triad Proteins 0.000 description 1
- 239000002117 illicit drug Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000001002 morphogenetic effect Effects 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/104—Lupus erythematosus [SLE]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Rehabilitation Therapy (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Rheumatology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30369110P | 2010-02-12 | 2010-02-12 | |
| US303691P | 2010-02-12 | ||
| PCT/IL2011/000153 WO2011099012A1 (en) | 2010-02-12 | 2011-02-13 | Diagnosis of systemic lupus erythematosus (sle) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2560809T3 true ES2560809T3 (es) | 2016-02-22 |
Family
ID=43971423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11711144.3T Active ES2560809T3 (es) | 2010-02-12 | 2011-02-13 | Diagnóstico de lupus eritematoso sistémico |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20130035254A1 (enExample) |
| EP (1) | EP2534487B1 (enExample) |
| JP (1) | JP5894539B2 (enExample) |
| CN (1) | CN102762983B (enExample) |
| AU (1) | AU2011213923A1 (enExample) |
| CA (1) | CA2789411A1 (enExample) |
| ES (1) | ES2560809T3 (enExample) |
| WO (1) | WO2011099012A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8652999B1 (en) | 2012-07-24 | 2014-02-18 | Dow Agrosciences, Llc. | Herbicidal compositions comprising 4-amino-3-chloro-5-fluoro-6-(4-chloro-2-fluoro-3-methoxyphenyl)pyridine-2-carboxylic acid or a derivative thereof and a sulfonylaminocarbonyltriazolinone |
| EP2698636A1 (en) * | 2012-08-13 | 2014-02-19 | Fundació Institut d'Investigació Biomèdica de Bellvitge | Methods and reagents for prevention and/or treatment of transplant rejection |
| US20160069896A1 (en) * | 2012-12-16 | 2016-03-10 | Yeda Research And Development Co., Ltd. | Diagnosis of autoimmune diseases using a specific antibody profile |
| CN104007266B (zh) * | 2013-02-27 | 2016-04-20 | 中国医学科学院基础医学研究所 | 含有6-n-甲基赖氨酸残基的抗原在制备辅助诊断系统性红斑狼疮试剂中的应用 |
| CN105229470B (zh) * | 2013-03-15 | 2018-11-27 | 艾克斯肯诊断股份有限公司 | 用于治疗和诊断系统性红斑狼疮的方法 |
| US20160320384A1 (en) | 2013-12-31 | 2016-11-03 | Yeda Research And Development Co. Ltd. | Methods for assaying immunological competence |
| EP3090064B1 (en) * | 2013-12-31 | 2019-11-13 | Yeda Research and Development Co. Ltd. | Diagnosis of systemic lupus erythematosus using oligonucleotides antigens |
| EP2933639A1 (en) * | 2014-04-16 | 2015-10-21 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | S100p and Hyaluronic acid as biomarkers for metastatic breast cancer |
| US20170045528A1 (en) * | 2014-04-25 | 2017-02-16 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating subjects with immune-mediated diseases |
| RU2017107273A (ru) * | 2014-08-08 | 2018-09-10 | Аллегени-Сингер Рисерч Инститьют | Антилимфоцитарные аутоантитела в качестве диагностических биомаркеров |
| US11047855B2 (en) | 2015-03-01 | 2021-06-29 | Immunarray Ltd. | Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens |
| WO2017223116A2 (en) | 2016-06-20 | 2017-12-28 | Healthtell Inc. | Methods for differential diagnosis of autoimmune diseases |
| WO2017223117A1 (en) * | 2016-06-20 | 2017-12-28 | Healthtell Inc. | Methods for diagnosis and treatment of autoimmune diseases |
| CN110168370A (zh) | 2016-11-11 | 2019-08-23 | 健康之语公司 | 用于鉴定候选生物标志物的方法 |
| BR112019010002A2 (pt) * | 2016-12-16 | 2019-08-20 | Merck Patent Gmbh | métodos para o uso de proteína de ligação galectina-3 detectada na urina para monitoramento da gravidade e progressão da nefrite lúpica |
| CN107151672B (zh) * | 2017-05-11 | 2021-05-28 | 成都医学院 | 一种重组质粒及其用途 |
| US11480568B2 (en) | 2017-09-28 | 2022-10-25 | Yeda Research And Development Co. Ltd. | Diagnosis of autoimmune diseases |
| BR102018075339A2 (pt) * | 2018-12-06 | 2021-11-16 | Fundação Oswaldo Cruz | Proteína recombinante, sequência de dna sintético, vetor de expressão, célula hospedeira, composição, kit para diagnóstico de rubéola, uso de pelo menos uma proteína recombinante, e, métodos para produzir uma proteína recombinante e para diagnóstico de rubéola |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552391A (en) * | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| WO2001082960A1 (en) * | 2000-04-28 | 2001-11-08 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of polyclonal b cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking cd1-mediated interactions |
| IL137460A0 (en) | 2000-07-24 | 2001-07-24 | Yeda Res & Dev | Identifying antigen clusters for monitoring a global state of an immune system |
| CA2430110C (en) * | 2000-11-27 | 2012-03-27 | Intelligent Medical Devices, Inc. | Clinically intelligent diagnostic devices and methods |
| ES2239532B1 (es) * | 2004-02-06 | 2006-11-01 | Proyecto De Biomedicina Cima S.L. | Metodo para evaluar el riesgo y la predisposicion a desarrollar una patologia relacionada con la presencia de autoanticuerpos frente a epcr. |
| US20050260770A1 (en) | 2004-04-01 | 2005-11-24 | Cohen Irun R | Antigen array and diagnostic uses thereof |
| US20070141627A1 (en) * | 2005-10-19 | 2007-06-21 | Behrens Timothy W | Systemic Lupus Erythematosus |
| WO2008064336A2 (en) * | 2006-11-22 | 2008-05-29 | Inivitrogen Corporation | Autoimmune disease biomarkers |
| CN101329341B (zh) * | 2008-07-09 | 2012-06-27 | 北京美康生物技术研究中心 | 检测自身免疫疾病相关抗核抗体谱的试剂盒及其制备方法 |
| EP2427767A4 (en) | 2009-05-05 | 2013-01-23 | Yeda Res & Dev | MEANS AND METHODS FOR RECOGNIZING THE DEVELOPMENT OF CARDIOVASCULAR DISEASE IN AN INDIVIDUAL |
-
2011
- 2011-02-13 ES ES11711144.3T patent/ES2560809T3/es active Active
- 2011-02-13 JP JP2012552519A patent/JP5894539B2/ja not_active Expired - Fee Related
- 2011-02-13 CA CA2789411A patent/CA2789411A1/en not_active Abandoned
- 2011-02-13 WO PCT/IL2011/000153 patent/WO2011099012A1/en not_active Ceased
- 2011-02-13 US US13/578,548 patent/US20130035254A1/en not_active Abandoned
- 2011-02-13 CN CN201180009356.6A patent/CN102762983B/zh not_active Expired - Fee Related
- 2011-02-13 AU AU2011213923A patent/AU2011213923A1/en not_active Abandoned
- 2011-02-13 EP EP11711144.3A patent/EP2534487B1/en not_active Not-in-force
-
2014
- 2014-07-31 US US14/449,124 patent/US20140342939A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2534487A1 (en) | 2012-12-19 |
| US20130035254A1 (en) | 2013-02-07 |
| US20140342939A1 (en) | 2014-11-20 |
| WO2011099012A1 (en) | 2011-08-18 |
| JP2013519875A (ja) | 2013-05-30 |
| CN102762983B (zh) | 2016-01-20 |
| AU2011213923A1 (en) | 2012-08-30 |
| CN102762983A (zh) | 2012-10-31 |
| JP5894539B2 (ja) | 2016-03-30 |
| EP2534487B1 (en) | 2015-11-04 |
| CA2789411A1 (en) | 2011-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Burbelo et al. | Luciferase immunoprecipitation systems for measuring antibodies in autoimmune and infectious diseases | |
| ES2345571T3 (es) | Ensayo y dispositivo para predecir el exito de un implante en tilizacion asistida. | |
| EP2992332B1 (en) | In vitro method for the early detection of a potential inflammation associated with rejection of a transplant | |
| ES2673697T5 (es) | Un ensayo de la respuesta inmunitaria mediada por células con sensibilidad incrementada | |
| KR20090003220A (ko) | 생체인식 분자에 접합된 마이크로비드를 사용하여 병원체를검출하는 방법 | |
| KR20210018771A (ko) | 마이크로 믹서 | |
| Saleh et al. | Evaluation of humoral immune response in adaptive immunity in ALS patients during disease progression | |
| JP2018521302A (ja) | アナライトの検出およびそのための方法 | |
| WO2021209565A2 (en) | In-vitro method and device for detecting a target nucleic acid and/or other macromolecules (such as peptides, proteins, carbohydrates or lipids) | |
| KR20170087169A (ko) | 생체분자의 계수분석 방법, 키트 및 장치, 그리고 그들의 이용 | |
| CN106568977A (zh) | 血清中sIL‑7R在诊断系统性红斑狼疮肾炎中的应用 | |
| CN1163755C (zh) | 诊断脱髓鞘病或海绵状病的试剂盒 | |
| Mirahmadi et al. | Frequency and parasite load of Toxoplasma gondii in hemodialysis patients based on RE gene by real-time PCR | |
| Norgard | Clinical and diagnostic issues of acquired and congenital syphilis encompassed in the current syphilis epidemic | |
| RU2314534C1 (ru) | Способ диагностики ревматических увеитов | |
| KR20170142157A (ko) | 생체분자의 계수분석 방법, 키트 및 장치, 그리고 그들의 이용 | |
| RU2314538C1 (ru) | Способ прогнозирования воспалительных осложнений при операциях, связанных с введением металлических конструкций в костную ткань | |
| ES2731908T3 (es) | Métodos de diagnóstico para el lupus | |
| SHIN et al. | The usefulness of PCR and early antigen immunostaining as a rapid identification method of cytomegalovirus infection | |
| RU2415439C1 (ru) | Способ дифференциальной диагностики увеита при ревматоидном артрите и болезни бехтерева | |
| TWI746966B (zh) | 糞便檢體檢查裝置、糞便檢體檢查方法 | |
| Francesca et al. | The possibility of using crystallography in the studying of leishmaniasis | |
| Midori et al. | Short-term follow-up analysis of plasma endotoxin levels to predict survival after surgical correction of displacement of the colon in horses: A retrospective case note analysis | |
| US20210324330A1 (en) | Methods for noninvasive detection, diagnosis and treatment of disease | |
| Al-Omary et al. | Lymphocyte Apoptosis in Third Trimester of Pregnancy. |